AEs occurring in 2% of patients in either group
| ICD (n=27) | Control (n=27) | |
| Any AE reported in study eye | 12 (44.4%) | 19 (70.3%) |
| Eye pain | 5 (18.5%) | 5 (18.5%) |
| Foreign body sensation | 5 (18.5%) | 3 (11.1%) |
| Myodysopsia (vitreous floaters) | 3 (11.1%) | 5 (18.5%) |
| Dry eye | 1 (3.7%) | 0 (0.0%) |
| Corneal oedema | 3 (11.1%) | 1 (3.7%) |
| Posterior capsule opacification | 1 (3.7%) | 2 (7.4%) |
| Macular oedema | 0 (0.0%) | 2 (7.4%) |
| Cystoid macular oedema* | 1 (3.7%) | 5 (18.5%) |
| Increase in IOP≥10 mm Hg between PODs 1 and 90 | 2 (7.4%) | 3 (11.1%) |
| Cataract progression in patients with phakic eyes | 4/12 (33.3%) | 12/16 (75.0%) |
| Cataract surgery performed in patients with phakic eyes | 0/12 (0.0%) | 1/16 (6.2%) |
*As determined by optical coherence tomography.
AEs, adverse events; ICD, intracameral dexamethasone; IOP, intraocular pressure; PODs, postoperative days.